At close: December 13 at 4:00:02 PM EST
After hours: December 13 at 4:20:00 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 7 | 14 | 16 |
| Avg. Estimate | -0.79 | -0.72 | -2.84 | -3.21 |
| Low Estimate | -1.01 | -0.99 | -3.12 | -4.36 |
| High Estimate | -0.08 | -0.31 | -2.13 | -1.7 |
| Year Ago EPS | -0.25 | -0.62 | -2.52 | -2.84 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 8 | 20 | 21 |
| Avg. Estimate | 14.81M | 16.16M | 53.84M | 69.14M |
| Low Estimate | 2M | -- | 42M | 15M |
| High Estimate | 65.7M | 41M | 105.3M | 163M |
| Year Ago Sales | 47.88M | 10.29M | 78.59M | 53.84M |
| Sales Growth (year/est) | -69.06% | 57.12% | -31.49% | 28.40% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.38 | -0.72 | -0.66 | -0.84 |
| EPS Actual | -0.25 | -0.62 | -0.58 | -0.82 |
| Difference | 0.13 | 0.1 | 0.08 | 0.02 |
| Surprise % | 33.63% | 14.04% | 12.01% | 2.93% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.79 | -0.72 | -2.84 | -3.21 |
| 7 Days Ago | -0.78 | -0.79 | -2.83 | -3.33 |
| 30 Days Ago | -0.78 | -0.79 | -2.83 | -3.33 |
| 60 Days Ago | -0.84 | -0.85 | -2.95 | -3.42 |
| 90 Days Ago | -0.85 | -0.87 | -2.95 | -3.47 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 11 | 3 | 7 | 5 |
| Up Last 30 Days | 11 | 3 | 7 | 5 |
| Down Last 7 Days | 1 | 2 | 2 | 6 |
| Down Last 30 Days | 1 | 2 | 2 | 6 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| KYMR | -215.48% | -16.42% | -12.56% | -13.03% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Initiated | BTIG: Buy | 12/10/2024 |
| Initiated | BMO Capital: Market Perform | 12/6/2024 |
| Upgrade | Wells Fargo: Equal-Weight to Overweight | 12/2/2024 |
| Initiated | Stephens & Co.: Overweight | 11/18/2024 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 11/6/2024 |
| Maintains | UBS: Buy to Buy | 11/4/2024 |
Related Tickers
NRIX Nurix Therapeutics, Inc.
20.27
-1.41%
EWTX Edgewise Therapeutics, Inc.
27.62
-1.88%
ARVN Arvinas, Inc.
19.50
-1.22%
NUVL Nuvalent, Inc.
86.86
+0.05%
RLAY Relay Therapeutics, Inc.
4.7100
-1.46%
APGE Apogee Therapeutics, Inc.
44.50
+0.41%
XENE Xenon Pharmaceuticals Inc.
40.05
+1.52%
IDYA IDEAYA Biosciences, Inc.
25.19
-2.29%
ORIC ORIC Pharmaceuticals, Inc.
8.52
+1.07%
CCCC C4 Therapeutics, Inc.
4.3800
+1.39%